BRIC Nations Slow to Join PIC/S Inspection Coordination Effort
This article was originally published in The Gold Sheet
Executive Summary
PIC/S could play an even greater role in coordinating drug GMP inspections if its members included inspectorates of all the major drug exporting nations. While India appears to lack interest, Japan, China and others have been working to qualify for membership.
You may also be interested in...
Agencies, Industry Look to Standardize, Focus Global Inspection Processes
PIC/S, the world’s ‘club’ of pharmaceutical inspectorates, is considering making life easier for manufacturers by helping members align their views on deficiencies and reduce inspection redundancies. But much depends on the club’s ability to bring more inspectorates into the fold, particularly those of the emerging BRIC nations.
Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections
As Asian drug regulatory authorities gain confidence in their ability to regulate new drug products, they are subjecting applicants to increasingly extensive chemistry, manufacturing and controls reviews, more like those of first-tier authorities in the U.S. and Europe.
‘Global Allegiance’ of Inspectorates Emerging
Drug regulatory agencies around the world are beginning to coordinate their inspection processes, which could reduce global drug manufacturers’ burden of hosting multiple GMP inspections.Some are piloting joint inspections, with a pilot for active pharmaceutical ingredient manufacturers concluding next month, and a second for drug product manufacturers under way.